Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.39−0.01 (-2.74%)
Close on Nov 20, 2026Market cap $94.94MP/E –Yield –
Outlook Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Outlook Therapeutics's free cash flow for the twelve months ending Sep 30, 2019 was -$32.73M. For fiscal 2019 it was -$32.73M. The highest annual figure on record is -$15.80M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | -$32.73M | – |
| FY2018 | Sep 30, 2018 | -$35.82M | – |
| FY2017 | Sep 30, 2017 | -$15.80M | – |
| FY2016 | Sep 30, 2016 | -$46.58M | – |
| FY2015 | Sep 30, 2015 | -$36.28M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$5.94M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$10.46M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$6.31M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$10.02M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$9.66M | -17383.5% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$8.70M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$7.71M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$9.75M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $55.87K | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$5.71M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$4.15M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$5.99M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$10.70M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$16.49M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$7.01M | – |
See a number that looks wrong?